HPV vaccine study for people with and without HIV
Part of Immune system & allergy, Infections clinical trials.
This study tests how well the Gardasil 9 HPV vaccine works in people assigned male at birth, including those with HIV and those taking hormone therapy. Results could help protect against HPV-related cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You were assigned male at birth.
- You have not had the Gardasil 9 vaccine, or you are unsure and were born before 2003.
- You either have HIV or do not have HIV.
- You may have taken or are currently taking estrogen or androgen blockers (hormone therapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the HPV vaccine works in women living with HIV and whether it helps make cervical cancer screening more accurate. If you are a woman with HIV between 21 and 40 years old and already part of certain other HIV studies, you may be able to join.
This trial studies how well the Gardasil-9 HPV vaccine triggers the body’s immune response in people living with HIV. It may help doctors understand the best way to protect against HPV-related cancers and infections in this population.
This study tests if a single dose of the HPV vaccine (Gardasil 9) can lower the amount of HPV virus in women who already have the virus, potentially reducing how easily it spreads. It will help us learn if vaccination can protect partners and communities.
This trial tests whether adding HPV vaccination to the cervical cancer screening plan—while you get care at HIV (ARV) clinics—improves prevention of cervical problems. It focuses on women with HIV aged 25–35 to help reduce HPV-related cervical disease over time.
This trial tests a new 15-valent HPV vaccine to see if it is safe and creates a strong immune response. If you are between 9 and 45 years old and have not had an HPV vaccine before, you may be able to join.
This trial tests whether an HPV vaccine (the nonavalent type) can help prevent the same precancerous lesions from coming back after treatment. It is for people who currently have a high-grade HPV-related lesion but have not yet been treated for it.
Hear when a new Human Papilloma Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.